Home
PCRX
PCRX News

Latest Pacira BioSciences Inc. (PCRX) News on November 27, 2025

Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors

Barrons.com

13 days ago

Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Zacks

a month ago

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

GlobeNewswire

a month ago

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a month ago

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

GlobeNewswire

a month ago

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

GlobeNewswire

a month ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

5 months ago

PCRX: What does Argus have to say about PCRX?

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Zacks

5 months ago

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

GlobeNewswire

5 months ago

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee

GlobeNewswire

6 months ago

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee

Argus Research

6 months ago

PCRX: Rating decreased to a HOLD

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%

Simply Wall St.

6 months ago

Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%

Argus Research

6 months ago

PCRX: Raising target price to $29.00

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

GlobeNewswire

6 months ago

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

GlobeNewswire

6 months ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Argus Research

6 months ago

PCRX: Lowering target price to $26.00

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

Zacks

7 months ago

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ...

GuruFocus.com

7 months ago

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ...

Associated Press Finance

7 months ago

Pacira: Q1 Earnings Snapshot

Pacira BioSciences Reports First Quarter 2025 Financial Results

GlobeNewswire

7 months ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings

GuruFocus.com

7 months ago

Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings

Argus Research

7 months ago

PCRX: Lowering target price to $28.00

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

GlobeNewswire

7 months ago

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

GlobeNewswire

7 months ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

GlobeNewswire

7 months ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

GlobeNewswire

7 months ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Argus Research

7 months ago

PCRX: Raising target price to $28.00

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

GlobeNewswire

7 months ago

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

PR Newswire

7 months ago

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

GlobeNewswire

7 months ago

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Argus Research

7 months ago

PCRX: Lowering target price to $27.00

Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?

Insider Monkey

7 months ago

Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Zacks

8 months ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks

8 months ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Pacira price target raised to $28 from $25 at Truist

TipRanks

8 months ago

Pacira price target raised to $28 from $25 at Truist

Argus Research

8 months ago

PCRX: Raising target price to $29.00

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

Zacks

8 months ago

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

GlobeNewswire

8 months ago

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

GlobeNewswire

8 months ago

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Argus Research

8 months ago

PCRX: Lowering target price to $26.00

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

8 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

8 months ago

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Argus Research

8 months ago

PCRX: Raising target price to $27.00

Pacira Surges 66.8% in Six Months: How Should You Play the Stock?

Zacks

8 months ago

Pacira Surges 66.8% in Six Months: How Should You Play the Stock?

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

GlobeNewswire

8 months ago

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

PR Newswire

8 months ago

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences and Golden Entertainment in the Box have been highlighted as Zacks Bull and Bear of the Day

Zacks

9 months ago

Pacira BioSciences and Golden Entertainment in the Box have been highlighted as Zacks Bull and Bear of the Day

Bull of the Day: Pacira BioSciences (PCRX)

Zacks

9 months ago

Bull of the Day: Pacira BioSciences (PCRX)

Argus Research

9 months ago

PCRX: Lowering target price to $25.00

Is Pacira BioSciences, Inc. (PCRX) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

9 months ago

Is Pacira BioSciences, Inc. (PCRX) the Best Small Cap Pharma Stock to Buy Now?

Earnings Update: Here's Why Analysts Just Lifted Their Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target To US$31.71

Simply Wall St.

9 months ago

Earnings Update: Here's Why Analysts Just Lifted Their Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target To US$31.71

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Pacira Biosciences Inc Earnings Call

Pacira BioSciences Inc (PCRX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

GuruFocus.com

9 months ago

Pacira BioSciences Inc (PCRX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

Associated Press Finance

9 months ago

Pacira: Q4 Earnings Snapshot

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

GlobeNewswire

9 months ago

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

GlobeNewswire

9 months ago

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

GlobeNewswire

9 months ago

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

What To Expect From Pacira BioSciences Inc (PCRX) Q4 2024 Earnings

GuruFocus.com

9 months ago

What To Expect From Pacira BioSciences Inc (PCRX) Q4 2024 Earnings

Argus Research

9 months ago

PCRX: Lowering target price to $26.00

Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term

Zacks

9 months ago

Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

GlobeNewswire

9 months ago

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

Argus Research

9 months ago

PCRX: Lowering target price to $28.00

Best Value Stocks to Buy for February 11th

Zacks

10 months ago

Best Value Stocks to Buy for February 11th

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Should You Buy Pacira (PCRX) After Golden Cross?

Zacks

10 months ago

Should You Buy Pacira (PCRX) After Golden Cross?

Argus Research

10 months ago

PCRX: Raising target price to $28.00

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

10 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Pacira Announces Updates to Board of Directors

GlobeNewswire

10 months ago

Pacira Announces Updates to Board of Directors

Argus Research

10 months ago

PCRX: Raising target price to $27.00

Argus Research

10 months ago

PCRX: Raising target price to $24.00

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

GlobeNewswire

10 months ago

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

10 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Argus Research

10 months ago

PCRX: Raising target price to $22.00

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Zacks

10 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

GlobeNewswire

a year ago

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

Benzinga

a year ago

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

GlobeNewswire

a year ago

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Argus Research

a year ago

PCRX: Lowering target price to $15.00

Here's Why Pacira (PCRX) is a Strong Momentum Stock

Zacks

a year ago

Here's Why Pacira (PCRX) is a Strong Momentum Stock

Argus Research

a year ago

PCRX: What does Argus have to say about PCRX?

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

PR Newswire

a year ago

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

Argus Research

a year ago

PCRX: Raising target price to $16.00

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

a year ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Argus Research

a year ago

PCRX: What does Argus have to say about PCRX?

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

GlobeNewswire

a year ago

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term

Zacks

a year ago

Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term

Argus Research

a year ago

PCRX: What does Argus have to say about PCRX?

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

GlobeNewswire

a year ago

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Argus Research

a year ago

PCRX: Lowering target price to $13.00

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

GlobeNewswire

a year ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/08/2024

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

Zacks

a year ago

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

Thomson Reuters StreetEvents

a year ago

Q3 2024 Pacira Biosciences Inc Earnings Call

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/07/2024

Share on Social Networks: